Tiziana Life Sciences CEO Ivor Elrifi joined Steve Darling from Proactive to discuss updated clinical findings from the company’s ongoing Expanded Access Program evaluating intranasal foralumab in patients living with non-active Secondary Progressive Multiple Sclerosis (SPMS). The newly released data, updated through March 2026 and reflecting patient outcomes from 14 individuals, continue to support the therapy’s safety profile while also demonstrating signs of meaningful clinical benefit. Elrifi explained that patients receiving intranasal foralumab have continued to tolerate the treatment well over extended periods, with no new safety concerns emerging during the evaluation period. The updated findings suggest encouraging trends toward stabilization of disability progression, an important consideration for patients with SPMS, where treatment options remain limited and disease progression can significantly impact quality of life. The company highlighted that disability was assessed using the Expanded Disability Status Scale (EDSS), a commonly used clinical measurement in multiple sclerosis studies. Results indicated favorable movement toward disease stabilization, while additional benefits were observed in patient-reported fatigue measures. Fatigue, one of the most challenging and persistent symptoms affecting individuals with multiple sclerosis, was assessed using the Modified Fatigue Impact Scale (MFIS). According to the updated data, nearly half of participating patients — 46% — experienced clinically meaningful improvements of four points or greater on the MFIS scale, suggesting potential quality-of-life benefits associated with treatment. Elrifi emphasized that foralumab represents a differentiated approach in neuroimmunology. He noted that the therapy is currently the only fully human anti-CD3 monoclonal antibody in clinical development and that its intranasal delivery mechanism could provide a novel pathway for immune system modulation. The company believes this approach may offer broader therapeutic potential across both neuroinflammatory and neurodegenerative diseases. The latest findings strengthen Tiziana’s growing body of evidence supporting foralumab’s development and reinforce the company’s strategy of advancing innovative therapies designed to address unmet needs in neurological disease treatment. #proactiveinvestors #tizianalifescienceslts #nasdaq #tlsa #newceo #ivorelrifi #Foralumab #SPMS #Biotech #ClinicalTrials #Neuroimmunology #HealthcareInnovation #DrugDevelopment #MedTech